These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 28892775)

  • 21. The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes.
    Nagpal P; Descalzi-Montoya DB; Lodhi N
    Cancer Rep (Hoboken); 2021 Apr; 4(2):e1311. PubMed ID: 33103852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.
    Roemer MG; Advani RH; Redd RA; Pinkus GS; Natkunam Y; Ligon AH; Connelly CF; Pak CJ; Carey CD; Daadi SE; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Shipp MA; Rodig SJ
    Cancer Immunol Res; 2016 Nov; 4(11):910-916. PubMed ID: 27737878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
    Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
    J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hodgkin lymphoma: Current and future therapeutic strategies].
    Turpin A; Michot JM; Kempf E; Mazeron R; Dartigues P; Terroir M; Boros A; Bonnetier S; Castilla-Llorente C; Coman T; Danu A; Ghez D; Pilorge S; Arfi-Rouche J; Dercle L; Soria JC; Carde P; Ribrag V; Fermé C; Lazarovici J
    Bull Cancer; 2018 Jan; 105(1):81-98. PubMed ID: 29289336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.
    El Halabi L; Adam J; Gravelle P; Marty V; Danu A; Lazarovici J; Ribrag V; Bosq J; Camara-Clayette V; Laurent C; Ghez D
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):257-266.e3. PubMed ID: 33277223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response.
    Ansell SM
    Cancer J; 2018; 24(5):249-253. PubMed ID: 30247261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy.
    Bryan LJ; Gordon LI
    Blood Rev; 2015 Jan; 29(1):25-32. PubMed ID: 25260226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.
    Paydas S; Bağır E; Seydaoglu G; Ercolak V; Ergin M
    Ann Hematol; 2015 Sep; 94(9):1545-52. PubMed ID: 26004934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.
    Reinke S; Bröckelmann PJ; Iaccarino I; Garcia-Marquez M; Borchmann S; Jochims F; Kotrova M; Pal K; Brüggemann M; Hartmann E; Sasse S; Kobe C; Mathas S; Soekler M; Keller U; Bormann M; Zimmermann A; Richter J; Fuchs M; von Tresckow B; Borchmann P; Schlößer H; von Bergwelt-Baildon M; Rosenwald A; Engert A; Klapper W
    Blood; 2020 Dec; 136(25):2851-2863. PubMed ID: 33113552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
    Gerhard-Hartmann E; Goergen H; Bröckelmann PJ; Mottok A; Steinmüller T; Grund J; Zamò A; Ben-Neriah S; Sasse S; Borchmann S; Fuchs M; Borchmann P; Reinke S; Engert A; Veldman J; Diepstra A; Klapper W; Rosenwald A
    Br J Haematol; 2022 Jan; 196(1):116-126. PubMed ID: 34520052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
    Matsuki E; Younes A
    Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma.
    Jain MD; Kuruvilla J
    Drugs; 2017 Oct; 77(15):1645-1655. PubMed ID: 28819821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting macrophages in classical Hodgkin's lymphoma may seem rational, but is it safe?
    Dasanu CA
    J Oncol Pharm Pract; 2012 Mar; 18(1):104-8. PubMed ID: 21248172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Not Available].
    Bounaix L; Bendouda M; Bay JO; Lemal R
    Bull Cancer; 2016 Nov; 103 Suppl 1():S160-S163. PubMed ID: 28057180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
    Hamid O; Carvajal RD
    Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New molecular targets in Hodgkin and Reed-Sternberg cells.
    Sadaf H; Ambroziak M; Binkowski R; Kluebsoongnoen J; Paszkiewicz-Kozik E; Steciuk J; Markowicz S; Walewski J; Sarnowska E; Sarnowski TJ; Konopinski R
    Front Immunol; 2023; 14():1155468. PubMed ID: 37266436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Standard therapies versus novel therapies in Hodgkin lymphoma.
    Gallamini A; Di Raimondo F; La Nasa G; Romano A; Borra A; Greco M
    Immunol Lett; 2013; 155(1-2):56-9. PubMed ID: 24140162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Checkpoint Inhibition in Hodgkin Lymphoma - a Review.
    Bröckelmann PJ; Engert A
    Oncol Res Treat; 2017; 40(11):654-660. PubMed ID: 29065424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
    Frydenlund N; Mahalingam M
    Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.
    Koh YW; Jeon YK; Yoon DH; Suh C; Huh J
    Tumour Biol; 2016 Jun; 37(6):7507-14. PubMed ID: 26678894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.